Idera Pharmaceuticals (IDRA) to Release Earnings on Thursday

Idera Pharmaceuticals (NASDAQ:IDRA) is scheduled to post its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect Idera Pharmaceuticals to post earnings of ($0.42) per share for the quarter.

IDRA stock traded up $0.07 during trading on Wednesday, hitting $2.49. The company had a trading volume of 35,086 shares, compared to its average volume of 204,673. The stock has a market cap of $70.33 million, a price-to-earnings ratio of -1.09 and a beta of 2.45. Idera Pharmaceuticals has a 52-week low of $2.25 and a 52-week high of $10.95. The firm has a 50 day moving average of $2.60.

Several research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Idera Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, July 4th. Wedbush reissued an “outperform” rating on shares of Idera Pharmaceuticals in a research report on Friday, May 3rd. Finally, ValuEngine raised shares of Idera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $10.65.

Idera Pharmaceuticals Company Profile

Idera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology in the United States. It offers Tilsotolimod, a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma, and colorectal cancer.

Featured Story: How does a margin account work?

Earnings History for Idera Pharmaceuticals (NASDAQ:IDRA)

Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with's FREE daily email newsletter.